綠葉製藥(02186.HK)3名投資者認購旗下博安生物1.68%股權
綠葉製藥(02186.HK)公佈再與3名投資者訂立新一輪認購協議,認購旗下博安生物,經上一輪另外2名投資者認購擴大後註冊資本合共1.68%的股權,注資總額爲現金約1.21億元人民幣。交易完成後,博安生物最大股東山東綠葉的持股比例,將由73.56%下降至72.32%。
若博安生物未能於2024年底前實現合資格上市,投資者有權要求山東綠葉購買投資者持有的全部博安生物股權,金額上限以相關投資者注資總額的兩倍爲限,即合共2.42億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.